Faster-acting insulin aspart

Switching to fast-acting insulin aspart is associated with an increased time in range and reduced glycemic variability, show data from a real-world observational study.

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.

Fast-acting insulin aspart results in equal, but not better, glycemic control to insulin aspart in adults whose long-standing type 2 diabetes is not adequately controlled with a basal–bolus regimen, a trial conducted in 17 countries suggests.

Fast-acting insulin aspart is as effective as insulin aspart for glucose control when used for continuous subcutaneous insulin infusion in adults with type 1 diabetes, results of the onset 5 study show.

The pharmacodynamics of faster-acting insulin aspart in children are similar to those in adults, suggesting its ability to improve postprandial glycemic control in children with type 1 diabetes, say researchers.